NorthStar’s facilities in Wisconsin house our Company Headquarters and production, R&D and manufacturing, as well as all of our other departments.

Company Headquarters and
Primary Manufacturing Locations

Beloit, WI

Corporate Headquarters

1800 Gateway Boulevard, Beloit, WI 53511

NorthStar’s corporate headquarters in Beloit house our executive, administrative, Quality Affairs/Regulatory Affairs, logistics and Copper-67 (Cu-67) production activities, customer care, and training teams.

Isotope Processing Facility

1800 Gateway Boulevard, Beloit, WI 53511

This 20,000 sq ft facility, completed in September 2019, is equipped with a chemical processing line, analytical testing and metallurgy laboratories, and radioactive storage. Regular production runs of Radiochemical Grade (RCG) Copper-67 (Cu-67) are conducted here. Currently, the building is undergoing a major infrastructure upgrade, including the addition of new processing lines and product hot cells. Additionally, work is in progress to retrofit previously installed hot cells, originally dedicated to the production of other isotopes, to enhance our Cu-67 output. These upgrades are part of our strategy to upscale processes and prepare for large-scale cGMP commercial production. Furthermore, this facility includes a cGMP-compliant CDMO suite for final dose products.

Copper-67 Accelerator Production Facility

1800 Gateway Boulevard, Beloit, WI 53511

Groundbreaking for this 30,000 sq. ft. facility took place in September 2019, and construction was completed in January 2021. The first pair of electron beam accelerators are operational and producing Cu-67 on a routine basis.

NorthStar’s unique and proprietary electron accelerator production facility and processes are designed to optimize efficiency throughout the production cycle. This setup allows us the flexibility to produce batches of various sizes based on market demand.

During the initial construction, site preparation was completed adjacent to the first building, allowing NorthStar to swiftly add up to three additional mirror-image accelerator facilities. These new facilities are planned to support the growing market demand for Cu-67 and other radioisotopes.

Sept 2019
Accelerator Production facility groundbreaking
Jan 2021
Facility construction completed
Apr 2021
Delivery of electron accelerator pair
Mid 2022
Electron accelerator pair and associated equipment operational
Mid 2023
Initial production of radiochemical grade Cu-67


1800 Gateway Boulevard, Beloit, WI 53511

Groundbreaking for this 30,000+ sq ft first-of-its-kind Actinium-225 (Ac-225) Production facility, dedicated exclusively to commercial-scale production of non-carrier added (n.c.a.) Ac-225, was celebrated in September 2021. The facility houses a Rhodotron® TT300 HE electron beam accelerator used solely for the production of Ac-225. This marks the third electron accelerator NorthStar has purchased from IBA. Utilizing design concepts and key learnings from our Mo-99 and Cu-67 programs, this facility will allow for more efficient and expedited completion timelines, with potential future expansion plans in mind.

Construction began in early 2022 with initial production of radiochemical grade Ac-225 planned for 2024. We expect submission of the Drug Master File to the U.S. Food and Drug Administration (U.S. FDA) in 2025.

Sept 2021
Facility Groundbreaking
Nov 2021
Orders placed for accelerators and essential long-lead items
Early 2022
Construction begins
LATE 2024
Initial production of radiochemical grade Ac-225
MID 2025
Drug Master File Submitted to FDA


1800 Gateway Boulevard, Beloit, WI 53511

NorthStar Medical Radioisotopes will be the first and only U.S. company housing world class, commercial-scale, multi-radioisotope production and radiopharmaceutical development services on one campus. Our new Radiopharmaceutical CDMO facility is located on our 55-acre campus in Beloit, Wisconsin, enabling collaborator companies to realize the logistical, regulatory and other efficiency benefits afforded by a single site location.

Groundbreaking for the new 52,000 sq ft, state-of-the-art Radiopharmaceutical CDMO facility occurred in November 2022. The facility is purpose-engineered to meet growing demands for therapeutic and diagnostic radiopharmaceuticals. Also designed with the needs of our partner companies in mind, the facility will offer the flexibility needed to support advancement of their products, from development to commercialization.

Oct 2022
Facility Groundbreaking
Early 2023
Construction begins
July 2024
Construction complete
Jan 2025
CDMO/CMO Production Operations Launch

Additional Facilities

1800 Gateway Boulevard, Beloit, WI 53511

NorthStar’s 55-acre Beloit campus has space for additional facilities that will support the production of other isotopes and related products as their development progresses.

Madison, WI

Research and Development

5249 Femrite Drive, Madison, WI 53718

Femrite Drive is our 10,000 ft2 facility that is the Research and Development center of expertise for our product development engineering, microbiology and science teams. This facility also houses state-of-the-art microbiology and radiochemistry laboratories to support analytical and product testing.

Research and Development

3060 Progress Road, Madison, WI 53716

Progress Road is a 10,000 ft2 facility that is the Research and Development center of expertise for our isotope production equipment and includes our process development engineering, material testing and chemistry development teams. This facility also houses state-of-the-art equipment for developing, testing and upgrading our novel isotope processing equipment.